Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
Clinical and Molecular Hepatology · 2025
DOI: 10.3350/cmh.2024.0819 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Hyung Joon Yim und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Korea University Ansan Hospital, Ansanl, Korea. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Tenofovir, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ildong Pharmaceutical Co., National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Background/Aims: Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy and safety of BSV in patients with CHB who switched from long-term TDF to BSV. This study aimed to evaluate the outcome of a 48-week BSV therapy in patients with CHB who switched from long-term TDF treatment.Methods: In this non-inferiority trial, 153 CHB patients treated with TDF for ≥48 weeks who had hepatitis B virus (HBV) DNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Korea University Ansan Hospital, Ansanl, Korea.
- Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea.
- Department of Internal Medicine, Korea University Guro Hospital, Seoull, Korea.
- Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
- Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
- Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
Förderung
- Ildong Pharmaceutical Co.
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Yim, H. J., Seo, Y. S., Kim, J. H., Kim, W., Jung, Y. K., Jang, J. Y., Lee, S. H., Kim, Y. S., Kim, C. W., Kim, H. S., Shim, J. J., Cho, E. Y., Kim, I. H., Lee, B. S., Lee, J. H., Kim, B. S., Jang, J. W., Lee, H. W., Kwon, J. H., …, & Yang, J. M. (2025). Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0819
Vancouver
Yim HJ, Seo YS, Kim JH, Kim W, Jung YK, Jang JY, et al. Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0819
BibTeX
@article{Yim2025,
author = {Yim, Hyung Joon and Seo, Yeon Seok and Kim, Ji Hoon and Kim, Won and Jung, Young Kul and Jang, Jae Young and Lee, Sae Hwan and Kim, Yun Soo and Kim, Chang Wook and Kim, Hyoung Su and Shim, Jae-Jun and Cho, Eun-Young and Kim, In Hee and Lee, Byung Seok and Lee, Jeong-Hoon and Kim, Byung Seok and Jang, Jeong Won and Lee, Hyun Woong and Kwon, Jung Hyun and Kim, Moon Young and Song, Do Seon and Park, Jung Gil and Lee, Yoon Seok and Yoon, Eileen L and Lee, Han Ah and Kang, Seong Hee and Yang, Jin Mo},
title = {Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial},
journal = {Clinical and Molecular Hepatology},
year = {2025},
doi = {10.3350/cmh.2024.0819}
}
EUVIMED